HC Wainwright & Co. Reiterates Buy on Nkarta, Maintains $23 Price Target
Buy Rating Confirmed: Expanding Potential of Nkarta's NKX019 in SLE Treatment
Express News | Nkarta Has Initiated An Investigator-sponsored Trial Of NKX019, A Cd19-directed Chimeric Antigen Receptor NK-cell Therapy For Systemic Lupus Erythematosus. In June 2024, Nkarta Initiated Ntrust-1 Phase 1 Trial Of NKX019 For Lupus Nephritis
Express News | Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating Nkx019 for Systemic Lupus Erythematosus
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
Sector Update: Health Care Stocks Gain in Afternoon Trading